02 Dec, 2019 · In News
02 Apr, 2020 · In Press Releases
World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies
12 Mar, 2020
The Nomination Committee of Bioservo Technologies AB (publ) has decided to propose to the Annual General Meeting the following proposals for the number of Board members and the election of Board members. The Nomination Committee proposes that the number of Board members on the Board should be six (6). The Nomination Committee proposes, for the period until the end of the next Annual General Meeting, re-election of the Board members Anders Lundmark, Runar Bjørklund, Karin Ruiz, Kunal Pandit and Nikolaj Sørensen, as well as new election of Claes Mellgren. As the Chairman of the Board, it is proposed that Anders Lundmark be re-elected. Hans von Holst has declined re-election.
Claes Mellgren founder of the AQ Group, a global manufacturer of components and systems for industrial customers, was also CEO for the company between the years 2010 and 2018. He has previously been production, logistics and site manager at different ABB units in Västerås. Claes is today mainly working as an angel-investor and has several board positions including AQ Group (Nasdaq Mid Cap), Note AB (Nasdaq Small Cap) and Automation Region. Claes has a Master of Science degree from the University of Linköping.
Questions are referred to:
Runar Björklund, Chairman of the Nomination Committee
About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient.
The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.
Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.
FNCA Sweden AB, +46(0)8 528 00399, email@example.com is the Company’s Certified Adviser on Nasdaq First North Growth Market.
For more information, please visit www.bioservo.com